An AD vaccine based on target epitopes attached to universal, highly immunogenic MultiTEP vaccine platform when combined with AdvaxCpG, a potent yet well tolerated adjuvant suitable for human use, induced extremely high antibody titers against both Aβ and tau, at levels not previously achieved in other studies. The gene discussed is MAPT; the disease is Alzheimer disease.